Test Price
36,000 AED✅ Home Collection Available
Homologous Recombination Deficiency (HRD) Genomic Signature Testing in UAE | 36000 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
Homologous Recombination Deficiency (HRD) Genomic Signature Testing is essential for evaluating cancer susceptibility and guiding targeted therapy, in full compliance with UAE medical standards.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed physicians.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
Homologous Recombination Deficiency (HRD) Genomic Signature Testing is a next‑generation sequencing (NGS) assay that evaluates tumor DNA for defects in homologous recombination repair pathways, guiding targeted therapy selection — particularly PARP inhibitors — for breast, ovarian, pancreatic, and prostate cancers.
| Feature | Our Test (HRD Genomic Signature) | Closest Alternative (BRCA1/2 Alone) |
|---|---|---|
| Precision | Genome‑wide HRD Score + BRCA status | Mutation‑specific, misses epigenetic silencing |
| Methodology | NGS (Next‑Generation Sequencing) | Sanger sequencing or limited panel |
| Speed & Actionability | 3‑4 weeks TAT; direct PARP inhibitor eligibility report | May require reflex testing, longer clinical decision time |
Physician Insight & Safety Protocols
Clinical Advisory
Do not discontinue prescribed medication without consulting your doctor. This test does not replace a comprehensive cancer management plan.
Exclusion Criteria & Emergency Red Flags
- Inability to provide adequate tumor tissue (biopsy or surgical specimen) or peripheral blood.
- Known allergy to local anesthetics if a tissue biopsy is required.
- Active anticoagulant therapy that cannot be safely interrupted for sample collection (requires physician clearance).
- Acute febrile illness or systemic infection at time of collection.
- ER Red Flags: If you experience severe pain, excessive bleeding, or signs of infection (redness, swelling, fever) after a biopsy, seek immediate medical attention.
Patient FAQ & Clinical Guidance
1. What is HRD testing, and how can it help me?
HRD testing identifies DNA repair defects in tumors, guiding targeted therapy choices for cancer patients.
This advanced genomic analysis measures genomic instability scores, including loss of heterozygosity, telomeric allelic imbalance, and large‑scale state transitions, which together predict sensitivity to PARP inhibitors. Results enable personalization of treatment for ovarian, breast, pancreatic, and prostate malignancies, often revealing therapeutic options that might otherwise be overlooked.
2. Why is HRD testing important for cancer patients in the UAE?
HRD testing provides critical information to refine cancer treatment plans, especially for PARP inhibitor eligibility.
By identifying homologous recombination deficiency, this test helps oncologists select the most effective targeted therapies, improving outcomes for patients with breast, ovarian, pancreatic, and prostate cancers. DNA Labs UAE performs this analysis under DHA-approved protocols and UAE federal laws.
3. What preparation is needed before sample collection?
No special fasting or medication changes are required unless directed by your physician.
You must provide a valid doctor’s prescription (except for surgery or pregnancy cases). Our team coordinates the collection of tumor tissue (from the pathology laboratory or a fresh biopsy) and a single peripheral blood draw. All tissue extraction is performed in a hospital setting by qualified medical staff.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License Number 1143 and adheres to all UAE federal laws governing health data and personal privacy.
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): Ensures secure handling and storage of your genomic data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: Governs the electronic transmission and storage of health information.
- Federal Decree-Law No. 4 of 2016 on Medical Liability: Protects patient safety and clinical consent practices throughout the testing process.
Clinical & Logistical Metadata
| Test Name | Homologous Recombination Deficiency (HRD) Genomic Signature Testing |
| Price (AED) | 36,000 AED |
| Turnaround Time | 3-4 Weeks |
| Sample Type / Matrix | Tumor tissue (FFPE or fresh) + Peripheral blood (EDTA) |
| Methodology Used | Next-Generation Sequencing (NGS) |
| ICD-10-CM Code | Z01.818, C50.9, C56 |
| LOINC Code | 96791-6 |
| DHA Facility License & Laboratory Address | License 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians